MPHASE TECHNOLOGIES INCORPORATED (OTCBB: XDSL) "Up 25.00% in morning trading"
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website at www.mpowertech.com.
MEDICAL CARE TECHNOLOGIES INCORPORATED (OTCBB: MDCE) "Up 12.50% in morning trading"
Medical Care Technologies Inc. is traded under the symbol "MDCE" on the OTCBB and is headquartered in Beijing, China. MDCE, through joint ventures or Chinese subsidiaries, develops a network of children's health facilities in the larger urban areas throughout China. Services are geared towards the advancing economic middle-class and upper class Chinese families. Specializing in the care of children between the ages of 3 to 16, MDCE's role is to enhance the overall well-being of the family and community and to expand its pediatric services to include preventative health and wellness education. MDCE, through its children's health facilities, will also distribute a diverse range of industry-leading pharmaceutical and nutraceutical product lines. MDCE's main mission is simple – to become a healthcare service provider leader in children's health.
ALEXZA PHARMACEUTICALS INCORPORATED (NASDAQ: ALXA) "Up 10.31% in morning trading"
Alexza Pharmaceuticals, Inc., a development stage company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system that vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The company’s clinical-stage product candidates comprise AZ-004 (staccato loxapine), which is licensed to Biovail Laboratories International SRL for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-007 (staccato zaleplon), which completed phase I status for the treatment of insomnia; and AZ-001 (staccato prochlorperazine) and AZ-104 (staccato loxapine, low-dose), phase II product candidates for the treatment of migraine headache. It also develops AZ-002 (Staccato alprazolam), which completed a phase 1 clinical trial in healthy subjects and a phase 2a proof-of-concept clinical trial in panic disorder patients for the treatment of panic attacks; and AZ-003 (Staccato fentanyl) that completed phase 1 clinical trial for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California.
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily stock alerts go to www.otcpicks.com to sign up.
Disclosure: OTCPicks.com and affiliates have been compensated four thousand dollars by the company for XDSL promotional email coverage.